A Phase 1 interventional study of RCI001 Eye Drops 0.25% and Placebo Eye Drops in Dry Eye, sponsored by Rudacure. Completed at 1 site in South Korea. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Rudacure · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Dry Eye Syndromes with a site in Korea, Republic of — 5 open to participants now, 6 under way, 1 of them phase 3. Dry Eye Syndromes · Korea, Republic of.
Among the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, this one is the 41st largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 in phase 1, and was the 56th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →5 of the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Huons Co., Ltd. · Sites in Korea, Republic of
Ages 19+
AJU Pharm Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Nu Eyne Co., Ltd. · Sites in Korea, Republic of
Ages 19–60
Hanlim Pharm. Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 40+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 19 Years to 50 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 17 · Phase 4 7
First in 2008; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 99 across the 52 interventional studies, 275 across the 4 observational. Of the 44 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 58 have an industry lead sponsor. The 10 most frequent:
Rudacure is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Rudacure has 2 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies in Dry Eye Syndromes with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07397949Samsung Medical CenterRebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery | 2026-12 |
| NCT07656688Huons Co., Ltd.Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate the safety, tolerability, and pharmacokinetics of RCI001 eye drops 0.25% in healthy adult male participants. Pharmacokinetics means how the study drug is absorbed, distributed, and eliminated from the body over time.
Participants who meet the study requirements will be randomly assigned to receive either RCI001 eye drops 0.25% or placebo eye drops. The study treatment will be administered to the left eye according to the assigned dosing schedule. The study includes single-dose administration schedules and multiple-dose administration schedules for up to 15 days.
The study will monitor safety and tolerability through adverse event assessments, vital signs, physical examinations, electrocardiograms, laboratory tests, eye symptom assessments, and ophthalmic examinations. Blood samples will be collected at scheduled time points to measure the concentration of RCI001 in the blood.
Approximately 40 healthy adult male participants are planned to take part in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: RCI001 Eye Drops 0.25%
Drug: Placebo Eye Drops
Drug: RCI001 Eye Drops 0.25%
Drug: Placebo Eye Drops
Drug: RCI001 Eye Drops 0.25%
Drug: Placebo Eye Drops
Drug: RCI001 Eye Drops 0.25%
Drug: Placebo Eye Drops
Drug: RCI001 Eye Drops 0.25%
Drug: Placebo Eye Drops
RCI001 eye drops 0.25% administered to the left eye according to the assigned dosing schedule.
Also known as: RCI001
Matching placebo eye drops administered to the left eye according to the assigned dosing schedule.
Also known as: Matching placebo
Number of Participants With Adverse Events
The number and percentage of participants with adverse events will be summarized by treatment group. Adverse events will be assessed for seriousness, severity, relationship to the study drug, action taken, outcome, and whether they are treatment-emergent adverse events.
Time frame: From informed consent through the post-study visit, up to Day 18 for single-administration cohorts and up to Day 32 for multiple-administration cohorts
Number of Participants With Clinically Significant Abnormalities in Safety Assessments
Safety assessments will include vital signs, physical examinations, 12-lead electrocardiograms, clinical laboratory tests, ocular symptom assessments, and ophthalmic examinations. Clinically significant abnormalities will be summarized by treatment group.
Time frame: From baseline through the post-study visit, up to Day 18 for single-administration cohorts and up to Day 32 for multiple-administration cohorts
Time to Maximum Plasma Concentration (Tmax) of RCI001 After Single Administration
Tmax will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 11
Maximum Observed Plasma Concentration (Cmax) of RCI001 After Single Administration
Cmax will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 25
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of RCI001 After Single Administration
AUClast will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 11.
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of RCI001 After Single Administration
AUCinf will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 11.
Terminal Elimination Half-Life (t1/2) of RCI001 After Single Administration
Terminal elimination half-life will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 11.
Apparent Clearance (CL/F) of RCI001 After Single Administration
CL/F will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 11.
Apparent Volume of Distribution (Vz/F) of RCI001 After Single Administration
Vz/F will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 11.
Time to Maximum Plasma Concentration at Steady State (Tmax,ss) of RCI001 After Multiple Administration
Tmax,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of RCI001 After Multiple Administration
Cmax,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Minimum Observed Plasma Concentration at Steady State (Cmin,ss) of RCI001 After Multiple Administration
Cmin,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Average Plasma Concentration at Steady State (Cavg,ss) of RCI001 After Multiple Administration
Cavg,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Trough Plasma Concentration (Ctrough) of RCI001 After Multiple Administration
Ctrough will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Area Under the Plasma Concentration-Time Curve Over the Dosing Interval at Steady State (AUCtau,ss) of RCI001 After Multiple Administration
AUCtau,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Terminal Elimination Half-Life at Steady State (t1/2,ss) of RCI001 After Multiple Administration
Terminal elimination half-life at steady state will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Apparent Clearance at Steady State (CLss/F) of RCI001 After Multiple Administration
CLss/F will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Apparent Volume of Distribution at Steady State (Vz,ss/F) of RCI001 After Multiple Administration
Vz,ss/F will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Peak-to-Trough Fluctuation (PTF) of RCI001 After Multiple Administration
PTF will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Plan to share: No — Individual participant data will not be made available to other researchers. The study has been completed and the results are planned to be submitted for publication. De-identified individual participant-level data are not planned for external sharing due to participant confidentiality, informed consent, regulatory, legal, and proprietary considerations related to the investigational drug product. Aggregate results may be disclosed through ClinicalTrials.gov, scientific publication, and/or regulatory submissions, as applicable.
Ran from Oct 2024 to primary completion in Aug 2025, 10 months.
Of 34 phase 1 interventional studies under Dry Eye Syndromes, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 10 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rudacure